---
title: "ENDRA Life Sciences Reports Q3 2025 Financial Results"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/266009967.md"
description: "ENDRA Life Sciences reported a Q3 2025 net loss of $1.6 million, down from $2.4 million last year. Operating expenses, including R&D costs, decreased. The company is focused on developing its liver fat measurement device and adopting a digital asset treasury strategy. Management aims to secure additional financing and achieve profitability while continuing innovation in medical technology."
datetime: "2025-11-15T04:14:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266009967.md)
  - [en](https://longbridge.com/en/news/266009967.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266009967.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/266009967.md) | [繁體中文](https://longbridge.com/zh-HK/news/266009967.md)


# ENDRA Life Sciences Reports Q3 2025 Financial Results

Endra Life Sciences ( (NDRA) ) has released its Q3 earnings. Here is a breakdown of the information Endra Life Sciences presented to its investors.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

ENDRA Life Sciences Inc. is a medical technology company focused on developing devices for liver fat measurement, primarily serving the healthcare sector with innovative solutions for metabolic disease detection. The company recently released its earnings report for the quarter ending September 30, 2025, highlighting significant financial metrics and strategic developments. ENDRA reported a net loss of $1.6 million for the quarter, a decrease from the $2.4 million loss in the same period last year. The company’s operating expenses also saw a reduction, with research and development costs dropping significantly. Despite the financial losses, ENDRA continues to pursue its strategic initiatives, including the development of its liver fat measurement device and the adoption of a digital asset treasury strategy. Looking ahead, ENDRA’s management remains focused on securing additional financing to support its operations and achieve profitability, while continuing to innovate in the medical technology space.

### 相关股票

- [Endra Life Sciences (NDRA.US)](https://longbridge.com/zh-CN/quote/NDRA.US.md)
- [ENDRA LIFE SCIENCES INC (29273B500.US)](https://longbridge.com/zh-CN/quote/29273B500.US.md)

## 相关资讯与研究

- [ENDRA Life Sciences Q4 net loss narrows](https://longbridge.com/zh-CN/news/281239377.md)
- [Tempus AI, Medtronic Report Positive Clinical Trial Results for Medical Alert System](https://longbridge.com/zh-CN/news/281383602.md)
- [08:05 ETPenguin Ai Launches Gwen, a Build-Your-Own AI Platform for Healthcare Operations](https://longbridge.com/zh-CN/news/281363782.md)
- [Blackstone announces final close of record $6.3 billion life sciences fund - the largest private fund dedicated to life sciences](https://longbridge.com/zh-CN/news/281041966.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/zh-CN/news/281311983.md)